Financial Performance - The company's total revenue for 2022 reached CNY 217.43 million, representing a year-on-year increase of 21.78%[4] - Net profit attributable to shareholders was CNY 42.89 million, up 22.69% compared to the previous year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 38.62 million, reflecting a growth of 16.11%[4] - Basic earnings per share increased to CNY 0.82, a rise of 22.69% year-on-year[4] Assets and Equity - Total assets at the end of the reporting period amounted to CNY 434.56 million, marking an 81.19% increase from the beginning of the year[4] - Shareholders' equity attributable to the company surged to CNY 283.83 million, a significant increase of 192.30%[4] - The company raised CNY 144 million through the public issuance of 16 million shares on December 16, 2022, contributing to the growth in total assets and equity[6] Revenue Sources and Cost Management - Revenue from high-flexibility intelligent packaging production lines grew by 72.78% year-on-year, contributing to the overall revenue increase[6] - The company reduced its sales expenses related to large-scale exhibitions by 66.13% due to pandemic-related cancellations[6] - Financial costs decreased by 24.90% as the company repaid high-interest bank loans, leading to a reduction in short-term borrowings[6]
春光药装(838810) - 2022 Q4 - 年度业绩